Mix&Go[™] – A Universal "Glue" For Clinical Diagnostics, Life Sciences and Beyond

Australian Microcap Investment Conference Melbourne, October 23, 2013 Dr. Geoff Cumming, CEO Anteo Diagnostics Ltd (ASX:ADO)



or personal use only


The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Anteo Diagnostics Overview



D evelops, manufactures and commercialises proprietary surface coatings for healthcare industry

anteo diagnostics

O ur Mix&Go[™] is a novel "glue" with a ubiquitous array of applications

Diagnostics (IVD) and Life Sciences (LS) – here and now

- Launch of commercial Mix&Go products in 2010
- Enables strong yet flexible binding of biomolecules to a broad variety of synthetic surfaces without causing damage to their structure or activity
- Improves the outcome of pathology tests, such as blood tests
- Commercial agreements with several companies: Bangs, Merck, Affymetrix, One World Lab, Gennova etc.
- Extensive patents protect technology and applications
- Cash flow positive through 2014

Bioseparations – the next opportunity

- Unique market opportunity to provide cost-effective solution
- Focus on rapidly growing therapeutics market
- Mix&Go makes it practical to replace current cumbersome methods with magnetic separation – a desirable but so far uneconomical solution

Anteo – Corporate Overview

anteo diagnostics

Proven Technology Platform

Patented Technology

Clear Development Path

Robust Deal Portfolio

Sound Commercialisation Strategy Revenues from product sales Royalties from license agreements Paid R&D collaborations with IVD & LS companies

Proprietary technology licensed to major international healthcare companies with additional deals anticipated

Significant and growing patent portfolio

Mix&Go development is progressing from diagnostics to next market sector: bioseparations Significant additional opportunities exist

Over 80 companies are actively assessing Mix&Go in-house or through collaborative work

Combination of licensing, collaborations and product sale provide diversified portfolio of revenue streams with clear path to profitability



or personal use only **Patents**

Commercial agreements

Partnership agreement with U.S. based One World Lab
Commenced paid feasibility study with global leader in lateral flow POC test manufacture
Sales partnership agreement with Spanish based Gennova Scientific or Europe & Latin America
easibility agreement with major global healthcare company for levelopment of a POC device
Commenced further paid studies with lateral flow POC company

06/13 Granted European patent

08/13 Filed 2 new patent applications

Government Grants

07/13 Received 2-year \$1.7m grant from Commercialisation Australia



Corporate Snaps	shot
ASX	ADO
Cash	\$3.10M
Market Cap.	\$49 M
52 week high	7c
52 week low	5 c
Shares on issue	770.4m
Shareholders	3,385
Avg. daily volume	1,492,505
Тор 20	36%
Directors/staff	17.8%

Major Shareholders

Shareholder	Ownership
First Cape Mgt Pty Ltd	10.02%
Austcorp 190 Pty Ltd	4.26%
Nimrod Finance Ltd	2.57%

Board

Mr. Mark Bouris – Non-Executive Chairman
Dr. Geoff Cumming – Chief Executive Officer
Ms. Sandra (Sam) Andersen – Non-Executive Director
Mr. Richard Martin – Executive Director
Dr. John Hurrell – Non-Executive Director

Executive Team

- Dr. Geoff Cumming Chief Executive Officer
- Dr. Joe Maeji Chief Scientific Officer
- Mr. Richard Martin Chief Financial Officer
- Dr. Tina Baumgartner VP Business Development & Marketing

Mix&Go – A Game Changing Technology



Surface coatings are crucial in many industries and serve many purposes, e.g.:

- Provide adhesive properties, i.e. act like a "glue"
- Confer optical properties
- Add magnetic or electrical properties

Mix&Go is a universal "glue" that is uniquely suited for applications in diagnostics and life sciences:

- Gentle "glue" that maintains the activity of fragile biomolecules
- Improves pathology tests → earlier disease detection
- Reduces cost of test development and manufacture
- Applicable to numerous large healthcare segments:
 - Pathology/diagnostic tests
 - Point-of-care diagnostics
 - Bioseparation
 - Drug discovery and development
- Well suited to "glue" in a variety of applications and industries outside of healthcare, e.g. Resources and Cleantech

Current Focus: Diagnostics and Life Sciences

anteo diagnostics

Laboratory Diagnostics



- Global IVD: \$44B (2011)
- Immunoassays: \$8.8B
- Drivers: aging population = more tests, higher Asian demand, technology innovations


Point-of-care

Rapid Test Products

Life Science R&D







• \$8 B (2011)


- \$38B (2017 forecast)
- Drivers: price pressure, lack of qualified staff, need for immediate information, decentralisation, bedside testing

• \$3.7B in 2012


- Drivers: decentralised testing, broadening applications, direct to consumer marketing
- Very large and diverse
- Drivers: price pressure, efficiency

Mix&Go – The Secret Sauce





Without Mix&Go



With Mix&Go

Consequences	Characteristics	Benefits
Vast majority of proteins are non- functional	Undamaged, fully functional proteins on surface	Increased performance Less non-specific binding Improved protein stability
Lower sensitivity, LOD, dynamic range	Less protein and/or beads required	Reduced cost Saves valuable, expensive proteins
More protein needed	Easy and fast to use and manufacture	Improves efficiency Simpler test procedures Manufacturing faster, easier, more scalable
	Improved reproducibility	Improved accuracy with improved %CV


The Proof Is In The Data



Sensitivity		Mix8	Go™	Traditional	Improvement
	IL4	0.05	pg/mL	0.2 pg/mL	4x
Sensitivity improvement 4 to 50-fold!	Troponin I	5 pg	g/mL	50 pg/mL	10x
	TNF-α	5 pg/mL		> 250 pg/mL	50x
	HBcAg	<10 pg/mL		150 pg/mL	15x
	TSH	<0.001	ulU/mL	0.006 uIU/mL	6x
Cost			Mix&	Go™	Traditional
More than 8-fold reduction in cost of goods sold	Capture antiboo concentrat	* * *	0.125	mg/mL	1.0 mg/mL
	cAb Cost per	Plate*	\$1	.10	\$8.80
	Plate Cos	st*	\$0	.55	\$4.92
	Total Co	st	\$1	.65	\$13.72



Stability even at high temperatures - better shelf life



Mix&Go – Better Tests Faster!

anteo diagnostics

Mix&Go can improve all aspects of test development and manufacture so better tests can be developed faster

Performance Is Key, e.g. sensitivity, limit of detection

Fast Development Increases speed to market

Less Raw Materials Improved margins



New Test Possible for fragile proteins

Ease of Manufacture User-friendly, stable, robust

Scalable From R&D to manufacturing without changes in procedure

Bioseparations – A Significant Market Opportunity

Bioseparation or How to Get a Pure Protein



Bioseparation: isolating rare proteins or cells from a complex mixture without contamination, e.g. the purification of

- Therapeutic antibodies/biologic drugs
- Vaccines for human and veterinary use
- Rare cells, e.g. stem cells or circulating tumor cells
- Proteins for R&D purposes

Anteo's Solution: Mix&Go

- Enables preferred magnetic isolation approach which currently is too expensive
- Easy scale-up from R&D batches to large scale manufacturing batches
- Easy to automate, a critical aspect in large scale manufacturing

Mix&Go can change the way proteins are purified, positively impacting large industries from biological drug and vaccine manufacturing to stem cell research

Bioseparation – The Opportunity

Current Approach Chromatography:

- Time consuming
- Expensive
- Hard to automate
- Capacity constraints

Alternative

Magnetic separation:

- Technically superior
- Currently unaffordable

Paradigm Shift

With Mix&Go magnetic separation can become reality

- technically superior solution
- economically advantageous

Large Opportunity

- Protein and protein drug manufacturing: \$3-5B
- Vaccine manufacturing: \$620M in 2015

Leverage Mix&Go in bioseparations to create significant long-term revenue streams for Anteo

Bioseparations: Why Now?

Internal Drivers

- Proof of concept Mix&Go approaches show better performance than conventional methods
- Improvement Mix&Go can generate novel, versatile approaches for bio-separation
- Patent Application Filed securing a strong IP position
- Opportunity to move up value chain
- Global network and relationships developed through Mix&Go that will fast-track market penetration

External Drivers


 Increased importance -Biologics/protein drugs play an ever more important role:7 out of the top 10 drugs sold in 2012 were biologics

anteo diagnostics

- Market need expressed desire by users to move to magnetic separation but unfavorable economics currently prevent that move
- Changing needs an ever increasing variety of biological molecules requiring new approaches


Additional Opportunities





Targets and Timeline





Keypoints



- Mix&Go is a proprietary platform technology with broad applicability in diagnostics, life sciences, bioseparations and beyond
- Mix&Go is proven licensed and gaining significant traction in commercial markets
- Mix&Go success means Anteo is becoming cash flow positive
- Focus on diagnostics and life sciences with expansion into bioseparations provides Anteo significant revenue opportunities
- Strong leadership Board and management team in place to drive growth
- Global team resources and network to capitalise on growth opportunity

Anteo's Mix&Go is an enabling technology beneficial to many industries and applications. Mix&Go is quickly gaining traction in the diagnostic and life sciences industries and has significant mid-term potential in bioseparations and long term in a large number of applications in health care and other industries.

Contact Information



or personal use only For more information please contact:

Thank you very much for your interest in Anteo Diagnostics

anteo diagnostics limited

ited

Dr Geoff Cumming CEO

Mobile: 0417 203 021 Email: geoff.cumming@anteodx.com

Tel: (61 2) 8823 3110 Fax: (61 2) 9252 8466 Suite 4, 26 Brandl Street Brisbane Technology Park QLD 4113, Australia